Subcutaneous deuterated substrate administration in mice: An alternative to tail vein infusion
Magnetic Resonance in Medicine · 2024
DOI: 10.1002/mrm.29888 ↗Kurz gefasst
Fachartikel in der Zeitschrift Magnetic Resonance in Medicine, 2024. Verfasst von Kyu-Ho Song und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Tail, Brain. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NICHD NIH HHS, NIBIB NIH HHS.
Abstract (Originalsprache)
Purpose
Tail‐vein catheterization and subsequent in‐magnet infusion is a common route of administration of deuterium ( 2 H)‐labeled substrates in small‐animal deuterium (D) MR studies. With mice, because of the tail vein's small diameter, this procedure is challenging. It requires considerable personnel training and practice, is prone to failure, and may preclude serial studies. Motivated by the need for an alternative, the time courses for common small‐molecule deuterated substrates and downstream metabolites in brain following subcutaneous infusion were determined in mice and are presented herein.
Methods
Three 2 H‐labeled substrates—[6,6‐ 2 H 2 ]glucose, [ 2 H 3 ]acetate, and [3,4,4,4‐ 2 H 4 ]beta‐hydroxybutyrate—and 2 H 2 O were administered to mice in‐magnet via subcutaneous catheter. Brain time courses of the substrates and downstream metabolites (and semi‐heavy water) were determined via single‐voxel DMRS.
Results
Subcutaneous catheter placement and substrate administration was readily accomplished with limited personnel training. Substrates reached pseudo‐steady state in brain within ∼30–40 min of bolus infusion. Time constants characterizing the appearance in brain of deuterated substrates or semi‐heavy water following 2 H 2 O administration were similar (∼15 min).
Conclusion
Administration of deuterated substrates via subcutaneous catheter for in vivo DMRS experiments with mice is robust, requires limited personnel training, and enables substantial dosing. It is suitable for metabolic studies where pseudo‐steady state substrate administration/accumulation is sufficient. It is particularly advantageous for serial longitudinal studies over an extended period because it avoids inevitable damage to the tail vein following multiple catheterizations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA.
- Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
- Department of Chemistry, Washington University, St. Louis, Missouri, USA.
- Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
- Department of the Alvin J Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA.
ORCID-Profile: Liu Lin Thio, Joseph J H Ackerman, Joel R Garbow
Förderung
- NCI NIH HHS
- NICHD NIH HHS
- NIBIB NIH HHS
- Dravet Syndrome Foundation
- Alvin J. Siteman Cancer Center
Zitieren
APA
Song, K. H., Ge, X., Engelbach, J. A., Thio, L. L., Neil, J. J., Ackerman, J. J. H., & Garbow, J. R. (2024). Subcutaneous deuterated substrate administration in mice: An alternative to tail vein infusion. Magnetic Resonance in Medicine. https://doi.org/10.1002/mrm.29888
Vancouver
Song KH, Ge X, Engelbach JA, Thio LL, Neil JJ, Ackerman JJH, et al. Subcutaneous deuterated substrate administration in mice: An alternative to tail vein infusion. Magnetic Resonance in Medicine. 2024. doi:10.1002/mrm.29888
BibTeX
@article{Song2024,
author = {Song, Kyu-Ho and Ge, Xia and Engelbach, John A and Thio, Liu Lin and Neil, Jeffrey J and Ackerman, Joseph J H and Garbow, Joel R},
title = {Subcutaneous deuterated substrate administration in mice: An alternative to tail vein infusion},
journal = {Magnetic Resonance in Medicine},
year = {2024},
doi = {10.1002/mrm.29888}
}
EUVIMED